CD8A and neoplasm: Predictably, vaccines containing TBVA Peptides (including the DC–Pool Peptide cohort) stimulated the strongest CD8+ TIL responses against tumor-derived pericytes or VECs that naturally express these antigens (Figure 1F; p < 0.0015 for TBVA Peptide-inclusive vaccines vs. all other treatments, with p = 0.44 for DC-TBVA Peptide vs. DC–Pool Peptide vaccines), although detectable pericyte/VEC-reactive CD8+ TILs were also identified in the DC–Lysate, DC-NeoAg Peptide, and DC-MAA Peptide vaccine cohorts.